A PHASE 1, SINGLE-CENTER, RANDOMIZED, VEHICLE AND WHITE PETROLATUM CONTROLLED, EVALUATOR BLINDED STUDY TO ASSESS THE SKIN IRRITATION POTENTIAL WITH A RANGE OF CONCENTRATIONS OF PF-06700841 CREAM IN ADULT JAPANESE HEALTHY PARTICIPANTS
Latest Information Update: 27 May 2019
At a glance
- Drugs Brepocitinib (Primary)
- Indications Alopecia areata; Vitiligo
- Focus Therapeutic Use
- Sponsors Pfizer
- 23 May 2019 Status changed from recruiting to completed.
- 17 Apr 2019 New trial record